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I. Introduction	  
	   It	  is	  estimated	  that	  25.8	  million	  children	  and	  adults	  in	  the	  United	  States	  have	  
Diabetes	  Mellitus,	  which	  is	  roughly	  8.3%	  of	  the	  population,	  and	  1.7	  new	  cases	  are	  
diagnosed	  each	  year	  (Butler,	  2003).	  	  There	  are	  two	  specific	  types	  of	  Diabetes:	  Type	  I	  and	  
Type	  II.	  Type	  I	  is	  genetic,	  and	  there	  is	  an	  insulin	  decrease	  due	  to	  autoantibodies.	  	  Type	  II,	  
which	  represents	  90-­‐95%	  of	  the	  Americans	  with	  Diabetes,	  is	  adult-­‐onset,	  also	  called	  
insulin-­‐resistant	  or	  insulin-­‐dependent.	  	  As	  Type	  II	  Diabetes	  progresses,	  the	  pancreatic	  
insulin-­‐producing	  β	  cells	  are	  lost,	  with	  up	  to	  45%	  loss	  in	  the	  most	  severe	  cases.	  There	  is	  a	  
theory	  that	  the	  protein	  Islet	  Amyloid	  Polypeptide	  (IAPP),	  which	  is	  secreted	  in	  the	  pancreas,	  
is	  involved	  in	  the	  destruction	  of	  β	  cells.	  It	  adopts	  a	  misfolded	  structure	  in	  a	  nearly	  
irreversible	  reaction,	  aggregates	  in	  the	  pancreas,	  and	  becomes	  toxic,	  as	  explained	  by	  the	  
toxic	  oligomer	  hypothesis	  (Buccianti,	  2002;	  Haataja	  et.	  al,	  2009).	  When	  IAPP	  aggregates	  
within	  the	  body,	  it	  kills	  β-­‐cells,	  and	  the	  pancreas	  decreases	  the	  release	  of	  insulin,	  causing	  
high,	  unregulated	  glucose	  levels	  (Neddenriep,	  2011).	  	  This	  has	  a	  direct	  correlation	  to	  
Diabetes	  and	  the	  progression	  of	  the	  disease.	  
	   IAPP	  has	  become	  a	  topic	  of	  research	  in	  order	  to	  combat	  Type	  II	  Diabetes.	  Recently,	  
zinc	  chloride	  in	  low	  concentrations	  was	  shown	  to	  significantly	  decrease	  IAPP	  aggregation	  
by	  slowing	  down	  or	  even	  inhibiting	  fiber	  formation	  (Brender	  et.	  al,	  2010).	  	  In	  this	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experiment,	  three	  metals	  (KCl,	  CaCl2,	  and	  CuCl2)	  were	  tested	  with	  human	  IAPP	  to	  see	  if	  they	  
slow	  down	  or	  prevent	  the	  aggregation	  of	  the	  protein.	  	  
II. Materials	  and	  Methods	  	  
10mM	  solutions	  of	  the	  metal	  cations	  were	  prepared	  in	  TRIS	  buffer,	  and	  Thioflavin	  T	  
assays	  were	  performed.	  Thioflavin	  T	  (ThT)	  is	  a	  fluorescent	  dye	  that	  binds	  to	  aggregated	  
IAPP.	  375uL	  of	  IAPP	  was	  speed	  vacuumed	  for	  10	  minutes	  to	  evaporate	  any	  liquid	  from	  the	  
sample,	  leaving	  only	  the	  dried	  amyloid	  polypeptides	  (two	  experimental	  tubes	  for	  the	  
cations,	  one	  for	  IAPP	  alone).	  135uL	  of	  TRIS	  buffer	  and	  15uL	  of	  metal	  cation	  solution	  was	  
added	  to	  the	  appropriate	  experimental	  tubes,	  and	  150uL	  of	  TRIS	  was	  added	  to	  the	  IAPP	  
control.	  They	  were	  incubated	  at	  37°C,	  and	  at	  5	  minute	  intervals,	  a	  17µL	  aliquot	  of	  the	  
sample	  was	  added	  with	  663µL	  of	  a	  fluorescent	  dye,	  Thioflavin-­‐T,	  and	  put	  into	  the	  
Fluorescent	  Spectrophotometer	  to	  measure	  ThT	  fluorescence.	  	  
If	  the	  ThT	  results	  seemed	  promising,	  then	  Atomic	  Force	  Microscopy	  (AFM)	  slides	  were	  
created.	  	  AFM	  uses	  an	  ultra-­‐fine	  needle	  
attached	  to	  a	  cantilever	  beam,	  and	  the	  
needle	  “feels”	  the	  surface	  of	  the	  sample,	  
creating	  an	  image	  of	  the	  peaks	  and	  
valleys.	  This	  is	  useful	  in	  visualizing	  IAPP	  
fibers	  on	  a	  slide,	  but	  since	  it	  is	  time	  
consuming,	  it	  is	  only	  employed	  when	  the	  
ThT	  results	  showed	  inhibition	  of	  IAPP	  
aggregation.	  	  
	   Figure	  1:	  Atomic	  Force	  Microscopy	  (AFM)	  diagram,	  
including	  the	  cantilever,	  laser,	  and	  photo	  detector.	  



















	  Figure	  2:	  ThT	  fluorescence	  of	  KCl	  and	  CaCl2	  displayed	  as	  percentage	  of	  IAPP	  control	  at	  the	  peak	  for	  
that	  trial.	  Standard	  deviations	  are	  shown	  as	  error	  bars.	  There	  was	  no	  significant	  inhibition	  of	  IAPP	  

















Figure	  3:	  ThT	  fluorescence	  of	  CuCl2	  as	  compared	  with	  IAPP	  control	  over	  one	  trial	  of	  35	  minutes.	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Figure	  4:	  AFM	  slides	  of	  (A)	  IAPP	  alone	  and	  (B)	  IAPP	  with	  CuCl2.	  The	  IAPP	  alone	  shows	  fibers,	  and	  
the	  CuCl2	  also	  shows	  fibers,	  meaning	  there	  was	  no	  inhibition	  of	  IAPP	  aggregation,	  but	  most	  likely	  




KCl	  (K+)	  and	  CaCl2	  (Ca2+)	  did	  not	  show	  significant	  inhibition	  of	  IAPP	  aggregation,	  as	  
seen	  in	  Fig.	  2.	  K+	  was	  93.86%	  and	  Ca2+	  was	  90.22%	  as	  compared	  with	  the	  IAPP	  control,	  so	  
practically	  no	  inhibition	  occurred.	  This	  data	  was	  expected,	  as	  these	  metals	  are	  not	  known	  
to	  inhibit	  IAPP,	  but	  the	  data	  was	  consistent	  enough	  to	  reject	  these	  metals	  as	  potential	  
therapies	  for	  Type	  II	  Diabetes.	  
CuCl2	  showed	  promising	  results	  from	  preliminary	  ThT	  fluorescence,	  as	  shown	  in	  Fig.	  3.	  
Over	  a	  35	  minute	  trial,	  CuCl2	  maintained	  a	  fluorescence	  level	  under	  200,	  and	  IAPP	  peaked	  
at	  25	  minutes	  at	  519.7.	  	  Because	  there	  was	  no	  peak	  in	  CuCl2,	  an	  AFM	  slide	  of	  the	  sample	  
was	  prepared,	  as	  shown	  in	  Fig.	  4.	  	  As	  compared	  with	  the	  IAPP	  alone,	  there	  were	  still	  fibers	  
on	  the	  CuCl2	  slide,	  so	  it	  cannot	  be	  concluded	  that	  Cu2+	  inhibited	  IAPP	  aggregation	  and	  fiber	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formation.	  	  It	  has	  been	  shown	  that	  Thioflavin	  T	  can	  bind	  to	  samples	  instead	  of	  IAPP,	  leading	  
to	  falsely	  low	  fluorescence	  results	  and	  false	  positives	  (Hudson	  et	  al,	  2009).	  	  This	  is	  possibly	  
what	  occurred	  with	  the	  Cu2+.	  
For	  future	  research,	  the	  metal	  samples	  could	  be	  tested	  using	  circular	  dichromism,	  
which	  gives	  real	  time	  results	  as	  opposed	  to	  in	  intervals,	  which	  would	  prevent	  the	  
possibility	  of	  “missing”	  the	  peak	  in	  aggregation	  (McLean	  &	  Balasubramaniam,	  1992).	  	  The	  
samples	  would	  also	  need	  to	  be	  tested	  on	  human	  cell	  cultures	  in	  vivo	  to	  see	  if	  they	  are	  
plausible	  for	  actual	  treatments	  of	  Type	  II	  Diabetes	  Mellitus.	  	  Finally,	  the	  IAPP	  sequences	  
between	  species	  that	  get	  Diabetes	  and	  those	  that	  do	  not	  should	  be	  compared,	  paying	  
particular	  attention	  to	  the	  SNNFGAILSS	  region	  (amino	  acids	  20-­‐29),	  which	  causes	  proteins	  
to	  fold	  in	  manner	  prone	  to	  amyloidogenesis	  (Westermark	  et	  al,	  1990).	  
Although	  this	  study	  was	  not	  particularly	  conclusive,	  it	  lays	  the	  groundwork	  for	  future	  
experiments	  and	  gives	  a	  foundation	  for	  further	  study	  of	  metal	  cations	  and	  their	  
interactions	  with	  the	  Type	  II	  Diabetes	  Mellitus	  protein	  IAPP.	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